Drug Trial Radar · NCT07697560
Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jun 10, 2026
Primary completion
Sep 25, 2026
Study completion Sep 25, 2026
Sponsor
- Lead sponsor
- AnHorn Medicines Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, parallel-group, single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of AH-008 administered as a single intravenous infusion in healthy adult subjects. Four sequential dose cohorts will be evaluated, each with sentinel dosing and SRC-reviewed dose escalation.
Conditions
- Chemotherapy-induced Peripheral Neuropathy (CIPN)
Interventions
AH-008 for Injection, 150 mgDrug
Lyophilized powder
AH-008 for Injection, PlaceboDrug
Lyophilized powder
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
- Incidence of Clinically Significant Vital Sign AbnormalitiesTime frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
- Incidence of Clinically Significant 12-Lead ECG AbnormalitiesTime frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
- Incidence of Clinically Significant Clinical Laboratory AbnormalitiesTime frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
- Incidence of Subjects with Infusion Site ReactionsTime frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
- Pharmacokinetic characterization of maximum observed plasma concentration (Cmax) of AH-008Time frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
- Pharmacokinetic characterization of time to maximum observed plasma concentration (Tmax) of AH-008Time frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
- Pharmacokinetic characterization of area under the plasma concentration-time curve (AUC) of AH-008Time frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
- Pharmacokinetic characterization of terminal elimination half-life (t½) of AH-008Time frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
- Pharmacokinetic characterization of cumulative amount of AH-008 excreted in urine (Ae0-t)Time frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
- Pharmacokinetic characterization of urine recovery rate of AH-008 (Ae%)Time frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Clinial Research Unit
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.